Literature DB >> 1307887

Sodium nitroprusside-induced cyanide intoxication and prevention with sodium thiosulfate prophylaxis.

V A Hall1, J M Guest.   

Abstract

Sodium nitroprusside is an antihypertensive agent used frequently in the critical care setting. Recently, the Food and Drug Administration (FDA) published a report that led to a labeling change emphasizing the pharmacokinetics of nitroprusside with metabolism to highly toxic cyanide. Although evidence validates that cyanogenesis occurs with nitroprusside administration, prevention and treatment of cyanide poisoning is rarely instituted in clinical practice. Simultaneous infusion of thiosulfate with nitroprusside provides the sulfur donor necessary to prevent cyanide accumulation. Cyanide combines with thiosulfate to form the less toxic sodium thiocyanate, which is then excreted. A 10:1 ratio of nitroprusside to thiosulfate in the infusion eliminates the possibility of cyanide intoxication without altering the efficacy of nitroprusside.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1307887

Source DB:  PubMed          Journal:  Am J Crit Care        ISSN: 1062-3264            Impact factor:   2.228


  13 in total

1.  Note of caution for the use of sodium nitroprusside in neonatal hypertension.

Authors:  Christian von Schnakenburg; Marcus Krüger
Journal:  Pediatr Nephrol       Date:  2004-08-25       Impact factor: 3.714

2.  Lactic acidosis caused by sodium nitroprusside in a newborn with congenital heart disease.

Authors:  Sascha Meyer; Ali Baghai; Nieves-Lucia Sailer; Sven Gottschling
Journal:  Eur J Pediatr       Date:  2005-01-22       Impact factor: 3.183

Review 3.  Current and newer agents for hypertensive emergencies.

Authors:  Alan Padilla Ramos; Joseph Varon
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

4.  Stability of Sodium Nitroprusside and Sodium Thiosulfate 1:10 Intravenous Admixture.

Authors:  Lucas T Schulz; Edmund J Elder; Karen J Jones; Ashwanth Vijayan; Benjamin D Johnson; Joshua E Medow; Lee Vermeulen
Journal:  Hosp Pharm       Date:  2010-10-01

5.  Use of levosimendan in critically ill patients with severe aortic stenosis and left ventricular dysfunction.

Authors:  Francisca Caetano; Paula Mota; Sérgio Barra; Inês Almeida; Ana Botelho; Joana Trigo; António L Marques
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-12

Review 6.  International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis Inhibitors.

Authors:  Csaba Szabo; Andreas Papapetropoulos
Journal:  Pharmacol Rev       Date:  2017-10       Impact factor: 25.468

Review 7.  Treatment of acute severe hypertension: current and newer agents.

Authors:  Joseph Varon
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis.

Authors:  W Frank Peacock; Joseph Varon; Ramin Ebrahimi; Lala Dunbar; Charles V Pollack
Journal:  Blood Press Suppl       Date:  2010-11-23

Review 9.  Perioperative hypertension management.

Authors:  Joseph Varon; Paul E Marik
Journal:  Vasc Health Risk Manag       Date:  2008

Review 10.  Clinical review: the management of hypertensive crises.

Authors:  Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2003-07-16       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.